Notice ID: 4292c8a189754fc8b56056415de493ccAward NoticeAwardedArchived
NOTICE OF AWARD COMPOUND PHARMACEUTICALS
Awarded on March 3, 2026. The description is published on SAM.gov: Full description on SAM.gov.
Awarded tounder W81K0026PA026 (source: SAM.gov award notice)• $582.4K
Overview
- Posted
- March 3, 2026
- Notice type
- Award Notice
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDepartment of the Army
Notice details
- Office
- US ARMY MEDICAL COMMAND.US ARMY HEALTH CONTRACTING ACTIVITY.W40M MRC0 WEST
- Place of performance
- Fort Hood, Texas, 76544
- Last updated
- Nov 2, 2026
- First published
- Last updated on SAM.gov
- Award date
- Mar 3, 2026
- Award amount (SAM.gov award notice)
- $582.4K
Identifiers
- Solicitation number
- W81K0026PA026
- Notice ID
- 4292c8a189754fc8b56056415de493cc
- Award number (PIID)
- W81K0026PA026
Description
No description in the SAM.gov data feed for this notice.
Award Overview
Award Number
W81K0026PA026
Award Amount (SAM.gov award notice)
$582.4K
Award Date
Mar 3, 2026
Awardee
Awardee UEI
LDNAY53JNV24
Awardee CAGE Code
895Y5
Awardee Address
Pittsboro, NC 27312, UNITED STATES
Original Solicitation
Notice ID: 4292c8a189754fc8b56056415de493cc
Posted Date: Mar 3, 2026
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- —Signed Jul 28, 2026
- $401.5KSigned Dec 16, 2025
- $194.1KSigned Dec 10, 2025
- $401.5KSigned Nov 14, 2025
- $401.5KSigned Sep 25, 2025
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Timothy T. Hoerz
Documents
No documents available.
Lifecycle
- 3Version 3Award NoticeArchivedCurrent
NOTICE OF AWARD COMPOUND PHARMACEUTICALS
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer. | - | Awarded | Open |
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice. | - | Special Notice | 10/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 10/26/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 08/27/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | - | Solicitation | 10/01/2026 |
Additional Details
Solicitation Number
W81K0026PA026
Archive Date
Mar 18, 2026
Office Address
JBSA FT SAM HOUSTON, TX, 78234-4504